| Ytd | -6.78% | |
| 1y | -58.53% |
| Open | 0.97 | Prev Close | 0.99 | Low | 0.97 | High | 1.00 | Mkt Cap | 11.37M |
| Vol | 43.35K | Avg Vol | 582.32K | EPS | -1.29 | P/E | N/A | Forward P/E | 0.07 |
| Beta | 1.47 | Short Ratio | 0.50 | Inst. Own | 3.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.06 | 200-d Avg | 1.11 | 1yr Est | 36.00 |
PHIO News
Phio invites individual and institutional investors as well as advisors and analysts, to attend onli
Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-7
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (N
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 Kin
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with
PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASD
Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale A
Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile
Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfil
Brings extensive experience in patient care, dermatologic research and commercialization King of Pru
The company has received multiple favorable patent actions encompassing three notices of allowance
Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds
Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ
Phio entered into a comprehensive drug substance services agreement with Nitto Denko Avecia, Inc. in
Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manu
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:
Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendFeatur
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst co
Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with
King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDA
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend
Recent Company Highlights Phio's lead clinical candidate, PH-762, is being evaluated as an intra
The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating D
Phio Pharma stock fell after a recent rally, despite strong Phase 1b trial results showing an 85% re
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy an
Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop
Nonclinical protocol study design accepted by FDAStudy to commence in First Quarter 2026King of Prus
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop
